Market focus Target pharmaceutical manufacturers and CROs seeking faster site identification and reduced trial timelines, with a compelling use case demonstrated by the SPSS module delivering significant time and cost savings in Phase II–IV studies.

Evidence-backed ROI Highlight measurable outcomes from the respiratory study, such as contracted sites in weeks, accelerated enrollment, and substantial cost savings, to build a value proposition around faster time-to-market and lower trial risk.

Strategic differentiation Position Event Simulation Modeling as a unique capability for optimizing site and investigator selection globally, offering a competitive edge against traditional methods and broadening appeal to sponsors with diverse geographies.

Upsell opportunities Leverage successful SPSS outcomes to expand contracts into full ESM modules, data analytics, and ongoing site optimization services for later-phase trials, potentially increasing average deal size.

Financing readiness With modest revenue scale and a high-value solution, target partnerships or channel relationships with large consulting firms and integrators to accelerate market penetration and credibility through established networks.